MaxCyte, Inc. (MXCT) News
Filter MXCT News Items
MXCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MXCT News Highlights
- For MXCT, its 30 day story count is now at 4.
- Over the past 12 days, the trend for MXCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MXCT are DEC, DOUG and MD.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
Hedge Funds Say These Penny Stocks Are Poised to ExplodeIn this article, we will take a detailed look at hedge funds say these penny stocks are poised to explode. To see more such stocks, click Hedge Funds Say These 5 Penny Stocks are Poised to Explode. Despite common belief, not all penny stocks are inherently risky and suitable only for short-term gains. Some penny stocks […] |
With 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsKey Insights Institutions' substantial holdings in MaxCyte implies that they have significant influence over the... |
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million ROCKVILLE, Md., Dec. 11, 2023 (GLOBE NEWSWIR |
Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler. |
Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler. |
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding MemberMaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicinesROCKVILLE, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Allianc |
MaxCyte, Inc. (LON:MXCT) Analysts Just Cut Their EPS Forecasts SubstantiallyToday is shaping up negative for MaxCyte, Inc. ( LON:MXCT ) shareholders, with the analysts delivering a substantial... |
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call TranscriptMaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript November 8, 2023 MaxCyte, Inc. misses on earnings expectations. Reported EPS is $-108.76589 EPS, expectations were $-0.1. Operator: Good day, and thank you for standing by, and welcome to MaxCyte’s Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the […] |
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue GuidanceROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced financial results for the third quarter ended September 30, 2023. Third Quarter and Recent Highlights Total revenue of $8.0 million in the third quarter of 2023, a dec |